Translocation of dopamine and binding of WIN 35,428 measured under identical conditions in cells expressing the cloned human dopamine transporter

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 354, Issue 3, 1996, Pages 295-304

  Reith, Maarten E A ^a   Xu, Cen ^a   Zhang, Lian ^a   Coffey, Lori L ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Cocaine; Dopamine uptake; Human dopamine transporter; WIN 35,428 binding

Indexed keywords

1 [1 (2 BENZO[B]THIENYL)CYCLOHEXYL]PIPERIDINE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; CARRIER PROTEIN; COCAINE; DOPAMINE; VANOXERINE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOPAMINE UPTAKE; DRUG RECEPTOR BINDING; DRUG TRANSPORT; GENE EXPRESSION; GLIOMA CELL; HUMAN; MOLECULAR CLONING; NONHUMAN;

EID: 0029835639     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00171060     Document Type: Article

References (64)

1. Amara SG, Kuhar MJ (1993) Neurotransmitter transporters: recent progress. Annu Rev Neurosci 16:73-93
2. 3H]GBR 12935 binding in vitro to rat striatal membranes: labeling of the dopamine uptake complex. J Neurochem 48:1887-1896
3. Bannon MJ, Granneman JG, Kapatos G (1995) The Dopamine Transporter. Potential Involvement in Neuropsychiatric Disorders. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, pp 179-188
4. Baumann MH, Char GU, De Costa BR, Rice KC, Rothman RB (1994) GBR 12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the rat. J Pharmacol Exp Ther 271:1216-1222
5. Berger P, Elsworth JD, Reith MEA, Tanen D, Roth RH (1990) Complex interaction of cocaine with the dopamine uptake carrier. Eur J Pharmacol 176:251-252
6. Boja JW, Kopajtic TA (1993) Ion channel inhibitors may function as potential modulators of cocaine binding. Neuropharmacology 32:229-234
7. 3H] cocaine in striatum and its relationship to the dopamine transporter. Membr Biochem 7:87-106
8. Carroll FI, Kotian P, Dehghani A, Gray JL, Kuzemko MA, Parham KA, Abraham P, Lewin AH, Boja JW, Kuhar MJ (1995) Cocaine and 3 beta-(4′-substituted phenyl)tropane-2 beta-carboxylic acid ester and amide analogues. New high-affinity and selective compounds for the dopamine transporter. J Med Chem 38:379-388
9. 1) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
10. Cook EH Jr, Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE, Leventhal BL (1995) Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 56:993-998
11. Daniels J, Williams J, Asherson P, McGuffin P, Owen M (1995) No association between schizophrenia and polymorphisms within the genes for debrisoquine 4-hydroxylase (CYP2D6) and the dopamine transporter (DAT). Am J Med Gen 60: 85-87
12. DeLean A, Munson PJ, Rodbard D (1978) Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 235:E97-102
13. Deutsch HM, Schweri MM (1994) Can stimulant binding and dopamine transport be differentiated? Studies with GBR 12783 derivatives. Life Sci 55: PL115-20
14. Eshleman AJ, Henningsen RA, Neve KA, Janowsky A (1994) Release of dopamine via the human transporter. Mol Pharmacol 45:312-316
15. Eshlcman AJ, Neve RL, Janowsky A, Neve KA (1995) Characterization of a recombinant human dopamine transporter in multiple cell lines. J Pharmacol Exp Ther 274:276-283
16. Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, Ravert HT, Dannals RF (1993) Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 34:423-431
17. Gelernter J, Kranzler HR, Satel SL, Rao PA (1994) Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. Neuropsychopharmacology 11:195-200
18. Giros B, Caron MG (1993) Molecular characterization of the dopamine transporter. Trends Pharmacol Sci 14:43-49
19. Gu H, Wall SC, Rudnick G (1994) Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity. kinetics, and ion dependence. J Biol Chem 269:7124-7130
20. Harder R, Bönisch H (1985) Effects of monovalent ions on the transport of noradrenaline across the plasma membrane of neuronal cells (PC-12 cells). J Neurochem 45:1154-1162
21. He X, Raymon LP, Mattson MV, Eldefrawi ME, De Costa BR (1993) Further studies of the structure-activity relationships of 1-[1-(2-benzo[b]thienyl)cyclohexyl]piperidine. Synthesis and evaluation of 1-(2-benzo[b]thienyl)-N,N-dialkylcyclohexylamines at dopamine uptake and phencyclidine binding sites. J Med Chem 36:4075-4081
22. Heron C, Costentin J, Bonnet JJ (1994) Evidence that pure uptake inhibitors including cocaine interact slowly with the dopaminc neuronal carrier. Eur J Pharmacol 264:391-398
23. Jacobs S, Chang K, Cuatrecasas P (1975) Estimation of hormone receptor affinity by competitive displacement of labeled ligand: effect of concentration of receptor and of labeled ligand. Biochem Biophys Res Commun 66: 687-692
24. 3H]mazindol binding sites from alkylation by N-ethylmaleimide. Eur J Pharmacol 227:411-415
25. Kitayama S, Shimada S, Donovan D, Uhl G (1992a) Dopamine transporter residues important for substrate transport and ligand recognition. Soc Neurosci Abstr 18: 1331
26. Kitayama S, Shimada S, Xu H, Markham L, Donovan DM, Uhl GR (1992b) Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc Natl Acad Sci USA 89:7782-7785
27. Krueger BK (1990) Kinetics and block of dopamine uptake in synaptosomes from rat caudate nucleus. J Neurochem 55: 260-267
28. Kuhar MJ, Ritz MC, Boja JW (1991) The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 14: 299-302
29. Lester HA, Mager S, Quick MW, Corey JL (1994) Permeation properties of neurotransmitter transporters. Annu Rev Pharmacol Toxicol 34:219-249
30. Levine M, Oxender DL, Stein WD (1965) The substrate-facilitated transport of the glucose carrier across the human erythrocyte membrane. Biochem Biophys Acta 109:151-163
31. 3H]cocaine binding sites in caudate-putamen. J Pharmacol Exp Ther 251:131-141
32. 3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane. Mol Pharmacol 36:518-524
33. 3H]BTCP. Neurosci Lett 101:234-238
34. 3H]BTCP, a phencyclidine derivative) binding to the dopamine uptake complex. Neuropharmacology 30: 591-598
35. McElvain JS, Schenk JO (1992) A multisubstrate mechanism of striatal dopaminec uptake and its inhibition by cocaine. Biochem Pharmacol 43:2189-2199
36. Molinoff PB, Wolfe BB, Weiland GA (1981) Quantitative analysis of drug-receptor interactions: II. Determination of the properties of receptor subtypes. Life Sci 29:427-443
37. Motulsky HJ, Mahan LC (1984) The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol 25:1-9
38. Munson PJ, Rodbard D (1980) Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107:220-239
39. Munson PJ, Rodhard D (1988) An exact correction to the Cheng-Prusoff correction [published erratum appears in J Recept Res 1989 90;9(6): 511]. J Recept Res 8: 533-546
40. Nelson PJ, Rudnick G (1979) Coupling between platelet 5-hydroxy-tryptamine and potassium transport. J Biol Chem 254: 10084-10089
41. Newman AH, Allen AC, Izenwasser S, Katz JL (1994) Novel 3 alpha-(diphenylmethoxy)tropane analogs: potent dopamine uptake inhibitors without cocaine-like behavioral profiles. J Med Chem 37:2258-2261
42. Persico AM, Vandenbergh DJ, Smith SS, Uhl GR (1993) Dopamine transporter gene polymorphisms are not associated with polysubstance abuse. Biol Psychiatry 34:265-267
43. Pifl C, Giros B, Caron MG (1993) Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J Neurosci 13:4246-4253
44. Reith MEA, Meisler BE, Sershen H, Lajtha A (1986) Structural requirements for cocaine congeners to interact with dopamine and serotonin uptake sites in mouse brain and to induce stereotyped behavior. Biochem Pharmacol 35: 1123-1129
45. Reith MEA, Zimanyi I. O'Reilly CA (1989) Role of ions and membrane potential in uptake of serotonin into plasma membrane vesicles from mouse brain. Biochem Pharmacol 38:2091-2097
46. Reith MEA, de Costa B, Rice KC, Jacobson AE (1992) Evidence for mutually exclusive binding of cocaine, BTCP, GBR 12935, and dopamine to the dopamine transporter. Eur J Pharmacol 227: 417-425
47. Reith MEA, Selmeci G (1992) Radiolabeling of dopamine uptake sites in mouse striatum: comparison of binding sites for cocaine, mazindol, and GBR 12935. Naunyn Schmiedeberg's Arch Pharmacol 345:309-318
48. Richelson E, Pfenning M (1984) Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104:277-286
49. Ritz MC, Cone EJ, Kuhar MJ (1990) Cocaine inhibition of ligand binding at dopamine. norepinephrine and serotonin transporters: a structure-activity study. Life Sci 46:635-645
50. Rosenthal HE (1967) A graphic method for the determination and presentation of binding parameters in a complex system. Anal Biochem 20:525-532
51. Rothman RB (1990) High affinity dopamine reuptake inhibitors as potential cocaine antagonists: a strategy for drug development. Life Sci 46:PL17-21
52. Rothman RB, Mele A, Reid AA, Alunne HC, Greig N, Thurkauf A, DeCosta BR, Rice KC, Pert A (1991) GBR 12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. Pharmacol Biochem Behav 40:387-397
53. 3H]DA-uptake-inhibition to transporter-binding-inhibition ratios for the in vitro evaluation of putative cocaine antagonists. Life Sci 53:PL267-72
54. Rudniek G, Clark J (1993) From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta 1144:249-263
55. Saadouni S, Refahi-Lyamani F, Costentin J, Bonnet JJ (1994) Cocaine and GBR 12783 recognize nonidentical, overlapping binding domains on the dopamine neuronal carrier. Eur J Pharmacol 268:187-197
56. Schömig F, Korber M, Bönisch H (1988) Kinetic evidence for a common binding site for substrates and inhibitors of the neuronal noradrenaline carrier. Naunyn Schmiedeberg's Arch Pharmacol 337:626-632
57. Shimada S, Kitayama S, Lin CL, Patel A, Nanthakumar E, Gregor P, Kuhar M, Uhl G (1991) Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA [published erratum appears in Science 1992 Mar 6;255 (5049): 1195]. Science 254:576-578
58. Simoni D, Stoelwinder J, Kozikowski AP, Johnson KM, Bergmann JS, Ball RG (1993) Methoxylation of cocaine reduces binding affinity and produces compounds of differential binding and dopamine uptake inhibitory activity: discovery of a weak cocaine antagonist. J Med Chem 36:3975-3977
59. Spealman RD (1993) Modification of behavioral effects of cocaine by selective serotonin and dopamine uptake inhibitors in squirrel monkeys. Psychopharmacology (Berl) 112:93-99
60. Uhl GR, Johnson PS (1994) Neurotransmitter transporters: three important gene families for neuronal function. J Exp Biol 196: 229-236
61. 3H]BTCP): a new phencyclidine analog selective for the dopamine uptake complex. Eur J Pharmacol 148:427-436
62. White TD (1975) Models for neuronal noradrenaline uptake. In: Paton DM (cd) The mechanism of neuronal and extraneuronal transport of catecholamines. Raven Press, New York, pp 175-193
63. Xu C, Coffey LL, Reith MFA (1995) Translocation of dopamine and binding of 2 beta-carbomethoxy-3 beta-(4-fluorophenyl) tropane (WIN 35,428) measured under identical conditions in rat striatal synaptosomal preparations. Inhibition by various blockers. Biochem Pharmacol 49:339-350
64. Zimanyi I, Lajtha A, Reith MEA (1989) Comparison of characteristics of dopamine uptake and mazindol binding in mouse striatum. Naunyn Schmiedeberg's Arch Pharmacol 340:626-632